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Abstract/Summary [this will be used for indexing services and does not appear with article] 
The wall-less, hemotropic, mycoplasma species Mycoplasma haemofelis, ‘Candidatus Mycoplasma 
turicensis’ and, to a lesser extent, ‘Candidatus Mycoplasma haemominutum’ have the potential to 
induce clinical hemolytic anemia in infected cats. Prevalence varies markedly between infecting 
species, complicated by a chronic carrier state. Accurate and prompt confirmation of infection and 
identification of the infecting hemoplasma species enables appropriate antibiotics (e.g. tetracycline; 
fluoroquinolone) to be prescribed. Although cats with hemoplasmosis respond rapidly to antibiosis 
and supportive care, initial monotherapy treatment rarely results in clearance of infection. A protocol 
now exists for the clearance of the most pathogenic feline hemoplasma M. haemofelis.  
 
 
Key Points (3–5) 
• Hemoplasmosis due to Mycoplasma haemofelis infection is an uncommon cause of potentially 
fatal, moderate-severe hemolytic anemia in cats. 
• ‘Candidatus Mycoplasma haemominutum’ infection, detected in approximately 20% of cats, 
can result in mild anemia; however, a subclinical carrier state is common. 
• Decision to treat should be based on accurate diagnosis of hemoplasma infection, including 
speciation, using molecular diagnostic techniques (i.e. PCR). 
• Tetracyclines (e.g. doxycycline) and fluoroquinolones (e.g. marbofloxacin; pradofloxacin) are 
considered appropriate choices of antibiotics for hemoplasmosis 
• Monotherapy rarely results in persistent clearance of infection; however, the chronic carrier 
state is uncommonly of clinical concern  
 
Introduction 
Hemotropic mycoplasmas (hemoplasmas) are wall-less bacteria that parasitize red blood cells. They 
can induce potentially life-threatening hemolytic anemia in a wide variety of mammals, including the 
domestic cat, where they are the agent of feline infectious anemia.  
 
What is in a name? 
Hemoplasmas were first described in laboratory rodents in the 1920s, appearing in association with 
anemia following splenectomy 1-3. Originally thought to be members of the Bartonella genus due to 
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their hemotropic properties, small size (<1μm), and suspected role of arthropods in their 
transmission, their re-classification within the order Rickettsiales in the family Anaplasmataceae was 
suggested a decade later due to their uncultivatable status and lack of cutaneous lesions 4. However, 
questions still remained as to the correct positioning of these organisms within the family 
Anaplasmataceae due to their lack of a cell wall, lack of flagellae, inability to invade erythrocytes, and 
apparent antibiotic sensitivities (resistant to penicillin; sensitive to tetracyclines). Following the 
advent of DNA sequencing and phylogenetic analysis based upon ribosome gene sequence 
comparisons, many of the hemoplasmas became officially reclassified as mycoplasmas 5-7. 
Reclassification remains incomplete, as the first description of the rodent hemoplasma Eperythrozoon 
coccoides pre-dates that of the type species for the Mycoplasma genus Mycoplasma mycoides 8.  
 
In 1942 the first description of such bacteria in association with anemia in a cat appeared, with the 
name Eperythrozoon felis 9. Further descriptions, using the name Haemobartonella felis, appeared 
shortly afterwards 10-12. Outside the USA, this feline hemoplasma continued to be referred to as E. 
felis into the 1970’s before it became universally known as H. felis, with subsequent re-classification 
as Mycoplasma haemofelis at the turn of the 21st century 7,13. Of note, by contrast with rodents and 
dogs, clinical disease was reported in cats that had not been splenectomized.   
 
Prior to gene-based phylogenetic analysis, it had been recognized that ‘H. felis’ existed in different 
forms of differing pathogenicities, with the “large” form (a.k.a. Illinois, Florida, Ohio and Oklahoma 
strains) most frequently associated with disease compared to the “small” form (a.k.a. California and 
Birmingham strains) 14. Ribosomal gene analysis (16S rRNA gene and rnpB) confirmed the presence of 
two distinct organisms, Mycoplasma haemofelis and ‘Candidatus Mycoplasma haemominutum’ 7,13,14. 
More recently a further feline hemoplasma ‘Candidatus Mycoplasma turicensis’ was described in 
association with hemolytic anemia 15. All three of these organisms have since been described 
worldwide, sometimes in combination, with variable prevalences 16. These prevalence studies, mostly 
based on convenience samples, have also described the detection of ‘Candidatus Mycoplasma 
haematoparvum’ and ‘Candidatus Mycoplasma haematoparvum’-like organisms in cats 17,18; however, 
their role in disease is unknown. 
 
Clinical relevance 
Many of the clinical signs reported with hemoplasmosis (lethargy, weakness, depression, collapse, 
pallor, tachycardia, dyspnea/tachypnea, cardiac ‘hemic’ murmur, hepatosplenomegaly, 
lymphadenopathy, dehydration, fever, weight loss, pica, icterus) result from anemia or the underlying 
immune-mediated process, which can be fatal in severe cases.  
 
The presence of a chronic carrier state has limited the ability of epidemiological studies to associate 
hemoplasma infection with disease. In experimental feline studies, acute infection with M. haemofelis 
often results in severe hemolytic anemia in previously immunocompetent cats 19-21. However, at other 
times, only mild anemia is seen and it has been suggested that age may play a role in outcome, with 
younger cats more likely to develop more severe anemia. Although experimental infection with ‘Ca. 
M. haemominutum’ and ‘Ca. M. turicensis’ can result in a decreased hematocrit, they are infrequently 
associated with clinical signs in the absence of concurrent disease or immunosuppression. It should be 
noted that these studies comprise only handful of hemoplasma isolates, and that it is unclear whether 
strains of differing pathogenicity exist within an individual species. Experimental studies have also 
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demonstrated protective immunity against re-challenge with the same hemoplasma species for both 
M. haemofelis and ‘Ca. M. turicensis’  22,23.  
 
Consistent with an immune-mediated hemolytic anemia, auto-agglutination or positive Coombs’ 
testing may be detectable during acute M. haemofelis infection 21. However, hemoplasmosis remains 
an infrequent cause of immune-mediated hemolytic anemia, positive auto-agglutination results or a 
positive Coombs’ test 24. 
 
Diagnosis 
Blood should be collected for analysis prior to the administration of any treatments, particularly 
antibiotics with known activity against mycoplasmas (i.e. tetracyclines and fluoroquinolones). 
 
Although, cytological detection of organisms during acute hemoplasmosis could be considered as a 
point-of-care test, this is limited by the experience of the slide reviewer, as misdiagnosis can 
potentially arise from artefact (stain precipitate, poor slide preparation), Howell-Jolly bodies and 
other infecting species. One study demonstrated that cytology has a sensitivity of 11.1 %, with a 
specificity of 84 % 25 while another reported a detection rate of 37.5 % based on blood smear 
examination, compared to 100 % for PCR in cats experimentally infected with M. haemofelis and ‘Ca. 
M. haemominutum’ 26. In addition, the presence of the anti-coagulants EDTA and heparin have been 
suggested to result in the disassociation of hemoplasmas from erythrocytes over time, necessitating 
the preparation of fresh blood smears if assessment for their presence is desired 27,28. Cytological 
visualization of organisms may not be possible for some hemoplasma species; for example, in cats 
experimentally infected with ‘Ca. M. turicensis’ blood copy numbers remain very low, even during 
acute infection 15,29. 
 
Accurate diagnosis is currently reliant on the detection of bacterial DNA using PCR assays, which have 
been repeatedly demonstrated to be both more sensitive and specific than cytology 14,19-21,26,30. 
Newer quantitative PCRs determine hemoplasma numbers within samples collected 18,31. In common 
with most PCRs, due to small volumes of reagents utilized in these assays, the limit of detection for a 
typical assay is 200 organisms per mL blood. This is based on the detection of a single copy of a target 
gene within the 5µL purified DNA added to the PCR reaction, where DNA is purified from blood and 
eluted in an equivalent volume, and where the gene is present in a single copy within the organism. 
 
In a US study of cats with signs consistent with hemoplasmosis 4.8% were found to be infected with 
M. haemofelis, 23.2% to be infected with ‘Ca. M. haemominutum’ and 6.5% to be infected with ‘Ca. 
M. turicensis’, of which 6.5% represented co-infections 32. A similar UK study found lower prevalences 
of hemoplasma infection, with 2.8% infected with M. haemofelis, 11.2% infected with ‘Ca. M. 
haemominutum’ and 1.7% infected with ‘Ca. M. turicensis’, of which 1.6% represented co-infections 
31. A higher prevalence of M. haemofelis (7.6%) was reported in a convenience sample population of 
cats, where 21.7% were also infected with ‘Ca. M. haemominutum’, although hematological 
parameters were not determined for these cats 33. However, where hemoplasma prevalence has been 
compared between anemic and non-anemic cats, some authors have found no detectable difference 
24,34, while another study reported that ‘Ca. M. haemominutum’-infected cats were less likely to be 




Due to the presence of a chronic carrier state, detection of lower pathogenicity hemoplasmas ‘Ca. M. 
haemominutum’ and ‘Ca. M. turicensis’ in an anemic cat should prompt continued investigation of 
concurrent contributory factors to the etiopathogenesis of the anemia. However, knowledge of their 
presence is of use when considering treatment options, particularly if these would involve immune 
suppression e.g. in the treatment of idiopathic immune-mediated hemolytic anemia or lymphoma, or 
where no additional factors are identified.  
 
It should be noted that the design of highly species-specific PCR assays can limit the detection of 
novel or incompletely described hemoplasmas. In the rare event that clinical suspicion persists, 
further advice from the laboratory performing the assay should be sought.  
 
Treatment  
When to treat 
Cats with severe anemia resulting in cardiovascular compromise, including those whose anemia is 
caused by hemoplasmosis, are fragile and require careful management pending confirmation of 
underlying etiology. However, confirmation of diagnosis by PCR is often subject to a time delay, as 
samples are submitted to external commercial laboratories. Clinical hemoplasmosis, when confirmed, 
can often be successfully managed with a course of an appropriate antibiotic (see below), in 
conjunction with basic supportive care 19,35-37.  
 
Despite clinical resolution of hemoplasmosis, infection will only be eliminated in a minority of cases, 
and some cats can spontaneously clear the infection without antibiotic treatment. It should be noted 
that the majority of cats found to be infected with hemoplasmas in prevalence studies, particularly 
those infected with ‘Ca. M. haemominutum’ or ‘Ca. M. turicensis’, were likely asymptomatic chronic 
carriers and that, for M. haemofelis and ‘Ca. M. turicensis’ at least, re-challenge with the original 
infecting species does not appear to result in clinical disease 22,23.  
 
In some situations, clearance of infection may be desirable in addition to clinical cure. For example, 
when the cat is immunocompromised by concurrent infection (particularly by retroviruses feline 
immunodeficiency virus (FIV) and feline leukemia virus (FeLV)), as a result of treatments administered 
such as chemotherapy, or following splenectomy. Clearance of infection may also be considered 
where the cat represents a risk to either other cats by both horizontal or vertical transmission, or to 
an immunocompromised owner 38. Although horizontal spread remains the most likely route of 
infection, a possible case of vertical spread from queen to litter of kittens resulting in clinical anemia 
has been described 39; unfortunately this study pre-dated molecular confirmation of infection and 
hemoplasma speciation. Molecular techniques have more recently strongly supported vertical 
transmission in ruminant species 40,41. Zoonotic M. haemofelis infection has been described in an HIV-
positive man with concurrent Bartonella henselae infection 38. The source of infection was suspected 
to have been one of the M. haemofelis-infected cats in the household. Human infections with swine 
and ovine hemoplasmas have also been reported 42,43. Finally, as was the case in the experimentally 
hemoplasma-infected cats included in a recent study 44, clearance of infection may be a requirement 
of re-homing. 
 
The consequences of the chronic hemoplasma infection (‘carrier state’) are poorly understood. 
Anemic-stress has been shown to be a trigger for myelogenous leukemia in susceptible rodents (e.g. 
irradiated rats and leukemia-prone RF strain of mice) 45,46. One early experimental study suggested 
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that cats infected simultaneously with FeLV and M. haemofelis were more likely to develop FeLV 
viremia and aplastic anemia than those not infected with M. haemofelis 47. In another, pre-existing 
retrovirus infection (FeLV or FeLV/FIV) in apparently healthy cats potentiated the severity of anemia 
following ‘Ca. M. haemominutum’ infection 48. The latter study also reported a high incidence of 
myeloproliferative disease (e.g. leukemia, myelodysplastic syndrome, lymphoma); however, the 
absence of a control population of hemoplasma uninfected cats limited conclusions. Further studies 
are required to determine the long-term impact of chronic hemoplasma infection on the risk of bone 
marrow disorders, particularly in association with retrovirus infection. 
 
Supportive management 
Where cats are dehydrated, which is very common in hemoplasmosis, fluid deficits and electrolyte 
imbalances should be addressed with isotonic crystalloids. Conversely, chronically anemic cats are at 
risk of fluid overload due to increased circulating volume that, particularly in the presence of occult 
cardiac disease, may precipitate congestive heart failure. Care should be taken where history, physical 
examination findings and clinicopathological results do not indicate the degree of chronicity. 
Following re-hydration, red cell parameters should be reassessed, as the severity of anemia may have 
been exacerbated. 
 
In cats where the anemia has rapidly developed or where the anemia is severe (12%), cardiovascular 
compromise may be evident, despite correction of fluid deficits. In such cases, administration of 
either whole blood, or preferably packed red blood cells, should be considered. AB system blood-
typing should be performed prior to the administration of the first unit, and a unit of the same type 
administered. Cross-matching has been recommended from four days after administration of the 
initial unit, although in some cats antibodies can be detected, by way of a positive cross-match result, 
as early as two days post-transfusion 49. Due to the presence of non-AB system feline erythrocyte 
antigens 50 some experts have advocated cross-matching the initial blood product, in addition to all 
subsequent ones; however, a recent study did not find that cross-matching the initial blood product 
altered outcome or post-transfusion red blood cell parameters 51. 
 
The role of corticosteroids in the management of hemoplasmosis is unclear. In M. haemofelis-infected 
cats, clinical signs have resolved without their administration 19,21, suggesting that they are not 
necessary. Moreover, immunosuppression induced by corticosteroid administration has been used in 
experimental studies with the aim of enhancing infection or inducing recrudescence of bacteremia 
15,44,52. Further studies are required to determine whether corticosteroids at any dose rate are 
detrimental or beneficial; however, it is generally accepted that they may be indicated pending 
confirmation of diagnosis. 
 
Specific management - hemoplasmosis 
Like their relatives the mucosal mycoplasmas, hemoplasmas lack a cell wall, and as such are 
inherently resistant to antibiotics that are cell wall active such as the -lactams (e.g. penicillin-
derivatives and cephalosporins) and glycopeptides (e.g. vancomycin). In addition, due to the parasitic 
nature of the hemoplasmas, they are predicted to be inherently resistant to anti-metabolite 
antibiotics (e.g. trimethoprim sulphonamide), as are the mucosal mycoplasmas. In contrast, both 
tetracyclines and fluoroquinolones have been shown to have efficacy for the treatment of clinical 




Antibiotics of the tetracycline group (e.g. oxytetracycline, doxycycline) inhibit protein synthesis by 
blocking access of transfer RNA molecules to the 30S ribosomal subunit and are considered 
bacteriostatic. In contrast, antibiotics of the fluoroquinolone group (e.g. enrofloxacin, marbofloxacin, 
pradofloxacin) interfere with DNA replication by inhibiting the bacterial gyrase and / or the 
topoisomerase IV enzyme and are considered bactericidal. Experimentally, there is a well-
characterized antagonism between fluoroquinolone ciprofloxacin and tetracycline in the killing of the 
model bacterium Escherichia coli 58,59. However, one report documents unpublished studies of 
Mycoplasma genitalium that provide evidence of a synergistic effect between moxifloxacin and 
doxycycline in moxifloxacin-susceptible strains 60.To date, there are no data to support concurrent 
administration of fluoroquinolones and tetracyclines for feline hemoplasmas other than a single case 
report of the successful management of hemoplasmosis in a human 61.   
  
In cats experimentally infected with M. haemofelis, rapid resolution of the clinical signs of 
hemoplasmosis occurred during the administration of both tetracycline (doxycycline 5 mg/kg orally 
twice daily for 14 days) and fluoroquinolones (enrofloxacin 5 mg/kg or 10 mg/kg orally once daily for 
14 days; marbofloxacin 2 mg/kg orally once daily for 28 days; marbofloxacin 2.75 mg/kg orally once 
daily for 14 days;  pradofloxacin 5 mg/kg or 10 mg/kg orally once daily for 14 days) 19,35,36,52. Where 
different antibiotics, and doses, were compared, none were found to be clinically superior 35,36, 
potentially due to low numbers in each treatment group. Simultaneous administration of tetracyclines 
and fluoroquinolones was also associated with a significant and marked decrease in M. haemofelis 
load. It should be noted that these studies included untreated control cats, all of whom recovered 
without antibiotic administration, with some being administered fluid therapy if dehydrated, 
inappetent or severely anemic. Clearance of M. haemofelis infection was not achieved in the majority 
of cases treated with doxycycline, enrofloxacin or marbofloxacin. Of the cats treated with 
pradofloxacin, although 50% (n=6) were initially negative by PCR, subsequently repeated testing 
found three of these to have very low hemoplasma copy numbers present, with a further two 
becoming intermittently PCR positive following immunosuppression 36.  
 
In cats experimentally infected with ‘Ca. M. haemominutum’, administration of marbofloxacin (2 
mg/kg orally once daily for 28-days) resulted in a significant decrease in hemoplasma load, compared 
to the non-treatment control group, although this response was less dramatic, delayed and was non-
sustained compared to the response of M. haemofelis-infected cats to marbofloxacin 19,57.  
 
One experimental study assessed the response of ‘Ca. M. turicensis’ infection to antibiosis, in a 
limited number of cats (n=3). After doxycycline treatment (10 mg/kg once daily for 14 days), one cat 
showed a sustained decline in hemoplasma load following treatment. The other two cats were initially 
administered marbofloxacin (2 mg/kg once daily for 10 days), with negative ‘Ca. M. turicensis’ PCRs 
obtained 4-days later; however, detectable hemoplasma loads were obtained on the 10th day of 
treatment. Treatment was switched to doxycycline (10 mg/kg once daily for 14 days), and negative 
‘Ca. M. turicensis’ PCR results were obtained 14-days later. Neither of these two cats were monitored 
further. A single case study describes the clearance of ‘Ca. M. turicensis’ from a naturally infected cat 
following a course of doxycycline (10 mg/kg once daily for 14 days), with no subsequent 
recrudescence 34.  
 
The European Advisory Board on Cat Diseases (ABCD) currently recommends doxycycline (10 mg/kg 
orally once daily or 5 mg/kg orally twice daily) as a first-line therapy for clinical hemoplasmosis, 
 
 7 
typically for 2–4 weeks 62. Due to the risk of esophagitis and stricture formation 63, particularly with 
the hyclate form of doxycycline, tablets or capsules should be administered followed by water or a 
small amount of food. Fewer adverse effects are reported when doxycycline is administered in 
divided doses or in the monohydrate form, such as those found in some liquid or paste formulations 
62. Fluoroquinolones could be considered as an alternative, although enrofloxacin should be avoided 
where possible due to risks of retinal toxicity and acute blindness 64, particularly where alternative 
fluoroquinolones are available.  
 
Specific management – chronic carrier status 
A recent study described a treatment protocol that consistently cleared M. haemofelis infection in a 
small number (n=15) of chronically infected cats 44. Furthermore, following immunosuppression 
recrudescence was not detected. The protocol comprised a course of doxycycline (5 mg/kg orally 
twice daily for 28 days) followed, if organisms were still detectable in the blood, by a course of 
marbofloxacin (2mg/kg orally once daily for 14 days). Delays of up to four weeks’ duration between 
the administration of doxycycline and marbofloxacin were not detrimental to outcome. It should be 
noted that to determine clearance of infection, the M. haemofelis qPCR was performed in 
quadruplicate / triplicate to increase assay sensitivity (from 200 copies per mL to 50-66 copies per 
mL) on a weekly basis. However, neither drug is labelled for the treatment of hemoplasmosis in the 
cat and the suggested course durations for both doxycycline and marbofloxacin were relatively long. 
These findings should not be extrapolated to other feline hemoplasmas. 
 
In case reports of canine and human hemoplasmosis with clinical remission and apparent clearance of 
infection, as demonstrated by serial PCR testing, treatments have comprised extended administration 
of either tetracycline alone 65 or combinations of tetracycline and fluoroquinolone 61. A dog infected 
with M. haemocanis was administered doxycycline for nearly 3 months 65. A second canine case 
infected with M. haemocanis, clinically responded to extended courses of antibiotics (2 months 
oxytetracycline followed by 8 months enrofloxacin), although persistent clearance of infection was 
not achieved 66. Both canine cases involved dogs that had been splenectomized for non-neoplastic 
disease. In a human infected with ‘Candidatus Mycoplasma haemohominis’ there was a marked 
clinical improvement (resolution of hemolytic anemia) and achievement of non-detectable 
hemoplasma levels in blood in response to doxycycline alone; however, relapse occurred following 
discontinuation 61. Clinical cure followed 6-months’ worth of both doxycycline and moxifloxacin, with 
a 1-year follow-up. 
 
Group considerations  
Arthropods, particularly the cat flea Ctenocephalides felis, have been implicated in the transmission of 
feline hemoplasmas; however, confirmation of transmission by fleas by experimental demonstration 
has been limited 67,68. Currently, regular administration of anti-ectoparasitic treatment seems prudent 
in cats. Aggressive interactions leading to the subcutaneous inoculation of infected blood have also 
been implicated in transmission of hemoplasma infection 69; therefore indoor housing and separation 
of cats between which aggressive interactions are known to have occurred also seems sensible. 
Spread of infection has also been reported between cats housed together in the absence of 
arthropods and without reports of aggressive interactions 68. Therefore, where the aim is to maintain 





Hemoplasmosis due to M. haemofelis infection is an uncommon cause of moderate-severe anemia in 
cats. In contrast, ‘Ca. M. haemominutum’ is detected in approximately one in every five cats, and can 
result in mild anemia during acute infection; however, as a carrier state is common, concurrent 
disease should be investigated in clinically anemic cats. Infection may be exacerbated by 
immunosuppression, therefore prompt identification of the infecting hemoplasma species and 
appropriate antibiotic administration (e.g. tetracycline; fluoroquinolone) is necessary. Although cats 
with hemoplasmosis respond rapidly to antibiosis and supportive care, initial mono-therapy courses 
rarely result in clearance of infection. A protocol now exists for the clearance of the most pathogenic 
feline hemoplasma M. haemofelis.  
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